A male adult is in a stable condition in a Hunter hospital with confirmed meningococcal disease. This is the fourth case of meningococcal disease from the Hunter New England region this year.
In 2016 there were ten confirmed cases of meningococcal disease in the Hunter New England Local Health District.
Close contacts of the case have been prescribed clearance antibiotics. There are no links between this case and any previous cases.
"Meningococcal disease may be very severe and the community needs to be on the alert for its symptoms. If anyone suspects meningococcal disease, they should seek medical attention immediately," Public Health Physician Dr Tony Merritt said.
Up to 10 per cent of patients with invasive meningococcal disease in Australia die as a result of the infection. The first symptoms of meningococcal disease may include pain in the legs, cold hands and feet and abnormal skin colour.
Later symptoms may include high fever, headache, neck stiffness, dislike of bright lights, nausea and vomiting, a rash of reddish-purple spots or bruises, and drowsiness. Babies with the infection can be irritable, not feed properly and have an abnormal cry.
"Meningococcal infection does not spread easily. It is spread by secretions from the nose and throat of a person who is carrying it and close and prolonged contact is needed to pass it on. It does not appear to be spread through saliva or by sharing drinks, food or cigarettes."
Dr Merritt stressed that while meningococcal disease could be serious, in most cases, early detection and treatment resulted in a complete recovery.
Most cases of meningococcal disease are seen in infants, young children, teenagers and young adults, although people of any age can be infected.
Several strains of meningococcal bacteria cause disease in Australia. Previously the meningococcal C strain was common, but this is now rare following introduction of meningococcal C vaccine on the National Immunisation Program in 2003. Other strains are currently more common, however, people who have had the meningococcal C vaccine should still be on the look out for symptoms.
"The number of cases of this rare disease has been falling over the past ten years due in part to the success of the meningococcal C vaccination program," Dr Merritt said.
The meningococcal C vaccine is recommended for all babies at 12 months of age.
Where suspected or confirmed meningococcal disease has been diagnosed, public health officials will arrange for information and clearance antibiotics to be provided to close contacts, such as other members of the person's household. The purpose of clearance antibiotics is to eradicate any meningococcal bacteria the contacts may be carrying to prevent further transmission of the disease.